UNI-BIO GROUP (00690) announced that its wholly-owned subsidiary Beijing Bogene Gene Technology Co., Ltd. (Beijing Bogene) has signed a strategic cooperation agreement with Kexing Biopharm Co.,Ltd. (Kexing Biopharm), granting Kexing Biopharm exclusive commercialization rights for the Group's innovative osteoporosis treatment drug Bogutai® in six countries (cooperation regions): Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.
Bogutai® is a next-generation osteoporosis treatment drug that can promote bone formation and increase bone density. As China's first approved pre-filled pen-type teriparatide injection, Bogutai® features an ultra-fine injection needle and precise dosing system, which can reduce patient discomfort, improve medication compliance, and provide patients with a more convenient and comfortable treatment experience. The drug is indicated for postmenopausal women at high risk of fractures, significantly addressing unmet medical needs in this field.
The cooperation regions have more than 10 million osteoporosis patients with a market size of nearly $1.5 billion. This collaboration provides an important opportunity for Bogutai® to enter these markets with substantial unmet needs.
Since its launch in China in March 2024, Bogutai® has achieved remarkable success, with revenue growing by 248.9% year-on-year in the first half of 2025. This partnership will continue this strong development momentum, with the potential to generate returns as early as the end of 2026, and the competitive pricing strategy will enable Bogutai® to achieve higher profit margins.
Kexing Biopharm Co.,Ltd. (688136.SH) is a leading innovative multinational biopharmaceutical company that has established and operates 6 overseas subsidiaries and offices. It has achieved market access and sales in dozens of countries and regions globally, including the EU, Brazil, Philippines, and Indonesia.
The Board believes that this cooperation represents a key milestone in the Group's global expansion strategy, not only consolidating its position in the osteoporosis treatment market but also bringing long-term value to shareholders.